<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10043">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00699153</url>
  </required_header>
  <id_info>
    <org_study_id>526</org_study_id>
    <nct_id>NCT00699153</nct_id>
  </id_info>
  <brief_title>Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery</brief_title>
  <official_title>Safety and Efficacy of Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the clinical safety and efficacy of loteprednol etabonate in an ophthalmic
      base, when compared to vehicle for the treatment of inflammation following cataract surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Participants With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0</measure>
    <time_frame>Postoperative day 8 (Visit 5)</time_frame>
    <safety_issue>No</safety_issue>
    <description>A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= &gt;30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Grade 0 (no) Pain</measure>
    <time_frame>Postoperative day 8 (Visit 5)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain: A positive sensation of the eye, including foreign body sensation, stabbing, throbbing, or aching. Grade 0 = None; 1=Minimal; 2=Mild; 3=Moderate; 4=Moderately Severe; 5=Severe</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants With Complete Resolution of Anterior Chamber Cells and Flare, at Each Visit.</measure>
    <time_frame>At each visit: Visit 4-7, postoperative days 3-18</time_frame>
    <safety_issue>No</safety_issue>
    <description>A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= &gt;30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Each Follow-up Visit in Anterior Chamber Cells and Flare</measure>
    <time_frame>Postoperative Day 3-18 (Each follow-up Visit 4-7)</time_frame>
    <safety_issue>No</safety_issue>
    <description>A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= &gt;30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Ocular Inflammation</condition>
  <arm_group>
    <arm_group_label>Loteprednol Etabonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loteprednol Etabonate 0.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of Ophthalmic Loteprednol Etabonate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol Etabonate</intervention_name>
    <description>Loteprednol Etabonate in an ophthalmic base will be administered to study eye 4 times a day(QID) for 14 days.</description>
    <arm_group_label>Loteprednol Etabonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle of Ophthalmic Loteprednol Etabonate</intervention_name>
    <description>Vehicle of ophthalmic loteprednol etabonate administered postoperatively to study eye 4 times a day(QID) for 14 days.</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects at least 18 years of age

          -  Subjects who have the ability to understand and sign an informed consent form and
             provide Health Insurance Portability and Accountability Act (HIPAA) authorization.

          -  Subjects who are candidate for routine, uncomplicated cataract surgery.

          -  Subjects who are not of childbearing potential or subjects who have a negative urine
             pregnancy test result at screening.

          -  Subjects must be willing and able to comply with all treatment and follow- up
             procedures.

        Exclusion Criteria:

          -  Subjects who have known hypersensitivity or contraindication to the study drug or its
             components.

          -  Subjects who have a history or presence of chronic generalized systemic disease that
             the investigator feels might increase the risk to the subject or compound the result
             of the study.

          -  Subjects who have a severe/serious ocular condition, or any other unstable medical
             condition that, in the Investigator's opinion, may preclude study treatment or
             follow-up.

          -  Subjects with elevated intraocular pressure (&gt;/= 21 mm Hg), uncontrolled glaucoma, or
             being treated for glaucoma in the study eye.

          -  Subjects who are monocular or have pinholed Snellen VA 20/200 or worse in the
             non-study eye.

          -  Subjects who have had ocular surgery in the study eye within 3 months or in the
             fellow eye within 2 weeks prior to the screening visit.

          -  Women who are pregnant or breast feeding.

          -  Subjects who have participated in an investigational drug or device study within the
             last 30 days.

          -  Subjects previously randomized in this study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Trusso</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cornerstone Eye Wear</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 4, 2015</lastchanged_date>
  <firstreceived_date>June 13, 2008</firstreceived_date>
  <firstreceived_results_date>July 9, 2010</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Loteprednol etabonate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 16 sites in the US. The first participant was enrolled June 20, 2008 and the last participant visit was May 1, 2009.</recruitment_details>
      <pre_assignment_details>405 participants, who were candidates for routine, uncomplicated cataract surgery were enrolled in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Loteprednol Etabonate</title>
          <description>Loteprednol Etabonate Ophthalmic Ointment 0.5%</description>
        </group>
        <group group_id="P2">
          <title>Vehicle</title>
          <description>Vehicle of Ophthalmic Loteprednol Etabonate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="203">Intent to treat population</participants>
                <participants group_id="P2" count="202">Intent to treat population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Travel Problem</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Loteprednol Etabonate</title>
          <description>Loteprednol Etabonate Ophthalmic Ointment 0.5%</description>
        </group>
        <group group_id="B2">
          <title>Vehicle</title>
          <description>Vehicle of Ophthalmic Loteprednol Etabonate</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="203"/>
                <measurement group_id="B2" value="202"/>
                <measurement group_id="B3" value="405"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="68.3" spread="9.13"/>
                <measurement group_id="B2" value="69.2" spread="9.36"/>
                <measurement group_id="B3" value="68.8" spread="9.24"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="115"/>
                <measurement group_id="B2" value="115"/>
                <measurement group_id="B3" value="230"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="88"/>
                <measurement group_id="B2" value="87"/>
                <measurement group_id="B3" value="175"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="182"/>
                <measurement group_id="B2" value="178"/>
                <measurement group_id="B3" value="360"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black/African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="29"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>American Indian/Alaskan Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawiian/Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0</title>
        <description>A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= &gt;30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.</description>
        <time_frame>Postoperative day 8 (Visit 5)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to treat population, subjects who had missing data or took rescue medication prior to visit 5 were imputed as no.</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol Etabonate</title>
            <description>Loteprednol Etabonate Ophthalmic Ointment 0.5%</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of Ophthalmic Loteprednol Etabonate</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="203"/>
                  <measurement group_id="O2" value="202"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0</title>
            <description>A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= &gt;30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="64"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Grade 0 (no) Pain</title>
        <description>Pain: A positive sensation of the eye, including foreign body sensation, stabbing, throbbing, or aching. Grade 0 = None; 1=Minimal; 2=Mild; 3=Moderate; 4=Moderately Severe; 5=Severe</description>
        <time_frame>Postoperative day 8 (Visit 5)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol Etabonate</title>
            <description>Loteprednol Etabonate Ophthalmic Ointment 0.5%</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of Ophthalmic Loteprednol Etabonate</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="203"/>
                  <measurement group_id="O2" value="202"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants With Grade 0 (no) Pain</title>
            <description>Pain: A positive sensation of the eye, including foreign body sensation, stabbing, throbbing, or aching. Grade 0 = None; 1=Minimal; 2=Mild; 3=Moderate; 4=Moderately Severe; 5=Severe</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="149"/>
                  <measurement group_id="O2" value="83"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Complete Resolution of Anterior Chamber Cells and Flare, at Each Visit.</title>
        <description>A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= &gt;30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.</description>
        <time_frame>At each visit: Visit 4-7, postoperative days 3-18</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol Etabonate</title>
            <description>Loteprednol Etabonate Ophthalmic Ointment 0.5%</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of Ophthalmic Loteprednol Etabonate</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="203"/>
                  <measurement group_id="O2" value="202"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants With Complete Resolution of Anterior Chamber Cells and Flare, at Each Visit.</title>
            <description>A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= &gt;30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Visit 4, postoperative day 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Visit 5, postoperative day 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="64"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Visit 6, posoperative day 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="107"/>
                  <measurement group_id="O2" value="42"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Visit 7, postoperative day 18</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Each Follow-up Visit in Anterior Chamber Cells and Flare</title>
        <description>A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= &gt;30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.</description>
        <time_frame>Postoperative Day 3-18 (Each follow-up Visit 4-7)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol Etabonate</title>
            <description>Loteprednol Etabonate Ophthalmic Ointment 0.5%</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of Ophthalmic Loteprednol Etabonate</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="203"/>
                  <measurement group_id="O2" value="202"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline to Each Follow-up Visit in Anterior Chamber Cells and Flare</title>
            <description>A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= &gt;30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.</description>
            <units>Composite scores</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Visit 4, postoperative day 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.2" spread="1.20"/>
                  <measurement group_id="O2" value="-0.6" spread="1.48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Visit 5, postoperative day 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.2" spread="1.51"/>
                  <measurement group_id="O2" value="-0.8" spread="1.81"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Visit 6, postoperative day 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.7" spread="1.58"/>
                  <measurement group_id="O2" value="-1.1" spread="1.94"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Visit 7, postoperative day 18</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.6" spread="1.59"/>
                  <measurement group_id="O2" value="-1.1" spread="2.01"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Following drug administration visit 3 (postoperative day 1) through visit 7 (postoperative day 18).</time_frame>
      <desc>Ocular treatment related ocular AE's in &gt;/= 5% of Study Eyes, Either Treatment Group, Prior to Rescue Medication Use - Safety Population 204 Loteptednol, 201 Vehicle.</desc>
      <group_list>
        <group group_id="E1">
          <title>Loteprednol Etabonate</title>
          <description>Loteprednol Etabonate Ophthalmic Ointment 0.5%</description>
        </group>
        <group group_id="E2">
          <title>Vehicle</title>
          <description>Vehicle of Ophthalmic Loteprednol Etabonate</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Blocked arteries</sub_title>
                <description>One subject had 2 events of blocked arteries</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pituitary tumor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fall/Hip fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="151" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Anterior chamber inflammation</sub_title>
                <description>Ocular TEAEs Related to Study Drug in Study Eyes, Either Treatment Group, Prior to Rescue Medication Use - Safety Population</description>
                <counts group_id="E1" events="119" subjects_affected="49" subjects_at_risk="204"/>
                <counts group_id="E2" events="241" subjects_affected="94" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Eye Pain</sub_title>
                <description>Ocular TEAEs &gt;/= 5% in Study Eyes, Either Treatment Group, Prior to Rescue Medication Use - Safety Population</description>
                <counts group_id="E1" events="119" subjects_affected="7" subjects_at_risk="204"/>
                <counts group_id="E2" events="241" subjects_affected="17" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Corneal Edema</sub_title>
                <description>Ocular TEAEs in &gt;/= 5% of Study Eyes, Either Treatment Group, Prior to Rescue Medication Use - Safety Population</description>
                <counts group_id="E1" events="119" subjects_affected="10" subjects_at_risk="204"/>
                <counts group_id="E2" events="241" subjects_affected="12" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Conjunctival Hyperemia</sub_title>
                <description>Ocular TEAEs in &gt;/= 5% of Study Eyes, Either Treatment Group, Prior to Rescue Medication Use - Safety Population</description>
                <counts group_id="E1" events="119" subjects_affected="6" subjects_at_risk="204"/>
                <counts group_id="E2" events="241" subjects_affected="15" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Ciliary Hyperemia</sub_title>
                <description>Ocular TEAEs in &gt;/= 5% of Study Eyes, Either Treatment Group, Prior to Rescue Medication Use - Safety Population</description>
                <counts group_id="E1" events="119" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E2" events="241" subjects_affected="13" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <description>Ocular TEAEs in &gt;/= 5% of Study Eyes, Either Treatment Group, Prior to Rescue Medication Use - Safety Population</description>
                <counts group_id="E1" events="119" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E2" events="241" subjects_affected="12" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <description>Ocular TEAEs in &gt;/= 5% of Study Eyes, Either Treatment Group, Prior to Rescue Medication Use - Safety Population</description>
                <counts group_id="E1" events="119" subjects_affected="4" subjects_at_risk="204"/>
                <counts group_id="E2" events="241" subjects_affected="12" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <description>Ocular TEAEs in &gt;/= 5% of Study Eyes, Either Treatment Group, Prior to Rescue Medication Use - Safety Population</description>
                <counts group_id="E1" events="119" subjects_affected="4" subjects_at_risk="204"/>
                <counts group_id="E2" events="241" subjects_affected="10" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with, the Sponsor and such that confidential or proprietary information is not disclosed. Prior to publication or presentation, a copy of the final text should be forwarded by the Investigator(s) to the Sponsor or its designee for comment.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Laura Trusso, MS.</name_or_title>
      <organization>Bausch &amp; Lomb, Inc.</organization>
      <phone>(585) 338-5561</phone>
      <email>laura.trusso@bausch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
